[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"maternal-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:maternal-hypertension":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100481599","phase-3-safest-choice-of-antihypertensive-regimen-for-postpartum-hypertension-100481599",false,"NCT05551104","Safest Choice of Antihypertensive Regimen for Postpartum Hypertension","Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)","SCARPH","Inclusion Criteria:\n\n* Female\n* Women who develop postpartum hypertension\\* after delivery of the placenta or chronic hypertensive postpartum women who require medication for blood pressure control.\n\n  * Postpartum hypertension requiring treatment are defined as systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than or equal to 90mmHg on at least 2 occasions at least 4 hours apart, or systolic blood pressure greater than or equal to 160mmHg or diastolic blood pressure greater than 110mmHg sustained for more than 15 minutes.\n\nExclusion Criteria:\n\n* History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema\n* Contraindication to either Nifedipine or Labetalol\n* HR \\\u003C60 or \\>110\n* Native language other than English or Spanish","FEMALE","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.",[27,28,29],"Postpartum Complication","Maternal Hypertension","High Blood Pressure",[31],"Postpartum Hypertension","RECRUITING","2026-02-02",{"date":35,"type":36},"2026-02-04","ACTUAL",{"date":38,"type":36},"2023-05-08",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Loma Linda University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100421367","sflt1plgf-and-planned-delivery-to-prevent-preeclampsia-at-term-100421367","NCT04766866","sFlt1\u002FPlGF and Planned Delivery to Prevent Preeclampsia at Term.","Protocol of the PE37 Study: A Multicenter Randomized Trial of Screening With sFlt1\u002FPlGF and Planned Delivery to Prevent Preeclampsia at Term","PE37","Inclusion Criteria:\n\n* Nulliparous women\n* Singleton pregnancies\n* \\>18 years old\n* 35.0-36.6 weeks of gestation\n* Maternal written consent form\n\nExclusion Criteria:\n\n* Fetuses\u002Fneonates with major malformations or genetic anomalies that could modify the timing of delivery or has an impact on obstetric outcome\n* Suspected fetal growth restriction (estimated fetal weight \\\u003C3 centile or between the 3rd and 10th centile together with abnormal Doppler in the mean uterine artery Doppler pulsatility index, or in umbilical artery pulsatility index or in the middle cerebral artery or in the cerebral umbilical index (CPR))\n* Participation in another interventional study that could modify the timing of delivery.",true,{"count":55,"type":21},9132,[57],"NA","* Preeclampsia (PE) affects \\~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal morbidity and mortality in the world.\n* Term PE accounts for 70% of all PE and a large proportion of maternal-fetal morbidity related with this condition. Prediction and prevention of term PE remains unsolved.\n* Previously proposed approaches are based on combined screening and\u002For prophylactic drugs, but these policies are unlikely to be implementable in many world settings.\n* Recent evidence shows that sFlt1-PlGF ratio at 35-37w predicts term PE with 80% detection rate.\n* Likewise, recent studies demonstrate that induction of labor (IOL) from 37w is safe.\n* The investigators hypothesize that a single-step universal screening for term PE based on sFlt1\u002FPlGF ratio at 35-37w followed by IOL from 37w would reduce the prevalence of term PE without increasing cesarean section rates or adverse neonatal outcomes.\n* The investigators propose a randomized clinical trial to evaluate the impact of a screening of term PE with sFlt-1\u002FPlGF ratio in asymptomatic nulliparous women at 35-37w. Women will be assigned to revealed (sFlt-1\u002FPlGF known to clinicians) versus concealed (unknown) arms. A cutoff of \\>90th centile will be used to define high risk of PE and offer IOL from 37w.\n* If successful, the results of this trial will provide evidence to support a simple universal screening strategy reducing the prevalence of term PE, which could be applicable in most healthcare settings and have enormous implications on perinatal outcomes and public health policies worldwide.",[60,61,28,62,63],"Preeclampsia","Intrauterine Growth Restriction","Neonatal Outcome","Perinatal Death",[65],"Preeclampsia, angiogenic factors, perinatal death, induction of labour","2025-02-17",{"date":68,"type":36},"2025-02-19",{"date":70,"type":36},"2021-03-02",{"date":72,"type":21},"2026-12-31",{"name":74,"class":43},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",21]